% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Aziz:140098,
author = {Aziz, Ahmad and van der Burg, Jorien M M and Tabrizi, Sarah
J and Landwehrmeyer, G Bernhard},
title = {{O}verlap between age-at-onset and disease-progression
determinants in {H}untington disease.},
journal = {Neurology},
volume = {90},
number = {24},
issn = {0028-3878},
address = {[S.l.]},
publisher = {Ovid},
reportid = {DZNE-2020-06420},
pages = {e2099-e2106},
year = {2018},
abstract = {A fundamental but still unresolved issue regarding
Huntington disease (HD) pathogenesis is whether the factors
that determine age at onset are the same as those that
govern disease progression. Because elucidation of this
issue is crucial for the development as well as optimal
timing of administration of novel disease-modifying
therapies, we aimed to assess the extent of overlap between
age-at-onset and disease-progression determinants in
HD.Using observational data from Enroll-HD, the largest
cohort of patients with HD worldwide, in this study we
present, validate, and apply an intuitive method based on
linear mixed-effect models to quantify the variability in
the rate of disease progression in HD.A total of 3,411
patients with HD met inclusion criteria. We found that (1)
about two-thirds of the rate of functional, motor, and
cognitive progression in HD is determined by the same
factors that also determine age at onset, with CAG
repeat-dependent mechanisms having by far the largest
effect; (2) although expanded HTT CAG repeat size had a
large influence on average body weight, the rate of weight
loss was largely independent of factors that determine age
at onset in HD; and (3) about one-third of the factors that
determine the rate of functional, motor, and cognitive
progression are different from those that govern age at
onset and need further elucidation.Our findings imply that
targeting of CAG repeat-dependent mechanisms, for example
through gene-silencing approaches, is likely to affect the
rate of functional, motor, and cognitive impairment, but not
weight loss, in manifest HD mutation carriers.},
keywords = {Age of Onset / Disease Progression / Humans / Huntington
Disease: epidemiology / Huntington Disease: genetics /
Huntington Disease: pathology},
cin = {AG Breteler 1},
ddc = {610},
cid = {I:(DE-2719)1012001},
pnm = {345 - Population Studies and Genetics (POF3-345)},
pid = {G:(DE-HGF)POF3-345},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:29743208},
pmc = {pmc:PMC5996832},
doi = {10.1212/WNL.0000000000005690},
url = {https://pub.dzne.de/record/140098},
}